Clinical trial · Interventional
Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea
Effectiveness of Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea: a Randomised Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Persistent dyspnea is a debilitating symptom, that is common and difficult to treat. This symptom is found in many different diseases including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and metastatic cancer. Dyspnea is associated with many other symptoms, including anxiety, depression, and fatigue and is responsible for a significant reduction in quality of life. To date, only opiates are recommended for the pharmacological treatment of persistent dyspnea. The effectiveness of hypnosis is well known in the treatment of anxiety and delivered to patients suffering from chronic dyspnea for this reason. One randomised controlled study has shown that a single 20-minute mindfulness sessions could significantly reduce general symptom burden and have a significant impact on anxiety and depression in palliative care patients. Furthermore, the intervention had no negative side effects. Our aim is to evaluate the effectiveness of three hypnosis sessions on breathlessness mastery in patients with persistent dyspnea, using as a primary outcome the mastery domain of a validated tool, the Chronic Respiratory Questionnaire (CRQ).
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer (With or Without Metastasis) | Malignant Neoplasm | ALIAS | 0.85 |
| Chronic Heart Failure (CHF) | — | UNRESOLVED | — |
| COPD | — | UNRESOLVED | — |
| Dyspnea | — | UNRESOLVED | — |
| Interstitial Lung Disease (ILD) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypnosis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Hypnosis
- description
- 3 hypnosis sessions separated by 15 days
- interventionNames
- Other: Hypnosis
- type
- NO_INTERVENTION
- label
- Usual Care
- description
- Usual care
Primary outcomes (1)
- measure
- Chronic Respiratory Questionnaire (CRQ): sub scale mastery
- timeFrame
- From enrollment to the end of the intervention at 6 weeks.
- description
- The CRQ is a validated 20-item health-related quality of life questionnaire in which experiences are rated on seven-point scales ranging from 1 (maximum impairment) to 7 (no impairment). The CRQ mastery is a domain of the CRQ which comprises four questions with a range of scores also ranging from 1 to 7
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged ≥ 18 years and * Primary diagnosis of metastatic cancer, COPD stage at least B or E, ILD, or CHF and * Dyspnea stage NYHA ≥ II or mMRC ≥ 2 Exclusion Criteria: * Have had hypnosis treatment in the last 12 months * Have an estimated life expectancy of less than 6 months * Have participated in pulmonary rehabilitation in the last 6 months * Have been hospitalised in the last month (30 days) * Are unable to come to the hospital for 3 outpatient consultations (1 every two weeks) * Have a condition that would interfere with their ability to respond to the questionnaires (i.e. cognitive impairment, hearing impairment, etc.) * Are not eligible for a hypnosis session due to a psychiatric disorder
References
Publications (0)
Data not yet available